Back to journals
Academic Journal

Biorxiv

50 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 50 psychedelic papers Blossom tracks from Biorxiv line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does Biorxiv carry?

Sourced

Tracked papers by publication year. Click a year for the running total.

10papers published in 2023

+43% vs 2022

26 published by 2023

Browse papers→

Don't read as the journal's total output: only the 50 of 50 tracked psychedelic papers from Biorxiv with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does Biorxiv publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Neuroimaging & Brain Measures
19
Depressive Disorders
14
Anxiety Disorders
7
Schizophrenia
6
Chronic Pain
5
Addiction & Substance Use
4
PTSD
4
Microdosing
3
Other
13

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does Biorxiv cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Psilocybin
22
LSD
21
Ketamine
10
DMT
7
5-MeO-DMT
5
MDMA
5
Ayahuasca
3
2C-X
1
Other
1

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

Biorxiv has 50 tracked papers indexed in Blossom (2017–2026) from 364 authors, most often covering Psilocybin, LSD and Ketamine, across Neuroimaging & Brain Measures, Depressive Disorders and Healthy Volunteers.

Published Papers

Open Accessmeta

Sex Differences in Acute Responses to Psychedelics: Evidence for Greater Subjective Intensity and Impairment in Female Participants

This pooled analysis (n=72; 31 male, 41 female) of two double-blind, placebo-controlled studies comparing psilocybin (15 mg), 2C-B (20 mg), and LSD (50 μg) in healthy volunteers found that female participants reported more intense acute subjective effects and greater perceived impairment than male participants across all three drugs, with no sex differences in empathy or peak drug concentrations, pointing to pharmacodynamic rather than pharmacokinetic causes.

Published
Journal
Biorxiv
Authors
Mason, N. L., Haijen-Bongers, E. C., Kuypers, K. P., Frick, A., Toennes, S. W., Mallaroni, P., Ramaekers, J. G.
Open Accessindividual

Divergent changes in perturbation-induced brain reconfiguration following depression treatment with psilocybin and escitalopram

This brain imaging study examined resting-state fMRI from people with major depressive disorder before and after treatment with psilocybin or escitalopram, using computer models to test how the brain responded to artificial perturbations. It found that psilocybin increased brain reconfiguration under perturbation, while escitalopram decreased it, suggesting different effects on brain flexibility and stability.

Published
Journal
Biorxiv
Authors
Dagnino, P. C., Acero-Pousa, I., Carhart-Harris, R., Erritzoe, D., Nutt, D. J., Kringelbach, M. L., Sanz Perl, Y., Deco, G.
Open Accessindividual

Single-nucleus transcriptomics reveals cell type-specific and time-dependent effects of psilocybin and ketamine on gene expression

This mouse study used single-nucleus RNA sequencing to examine how psilocybin and ketamine change gene expression in the medial frontal cortex over time. It found cell type-specific effects, with psilocybin altering genes linked to synaptic plasticity, metabolism and glial function, and its transcriptional response peaking earlier and later than ketamine’s.

Published
Journal
Biorxiv
Authors
Liao, C., O’Farrell, E., Weiner, A. M., Qalieh, Y., Savalia, N. K., Girgenti, M. J., Kwan, K. Y., Kwan, A. C.
Open Accessmeta

A Shared Entropic Axis Spans States of Consciousness Across Pharmacological and Clinical Conditions

This brain imaging study compared fMRI data from psychedelics, modafinil, propofol anaesthesia and schizophrenia, and found that brain activity could be arranged along a single entropy-based axis of consciousness. Propofol sat at the low-entropy end, while psychedelics and schizophrenia were at the high end, with the pattern not explained by average functional connectivity.

Published
Journal
Biorxiv
Authors
Galvan Rial, D. S., Della Bella, G. A., Naci, L., Delli Pizzi, S., Sensi, S., Osan, T. M., Aguilera, D., Timmermann, C., Carhart-Harris, R., Stamatakis, E. A., Barttfeld, P.
Open Accessindividual

Distinct brain responses to psilocybin and escitalopram in depression captured by the Fluctuation-Dissipation Theorem

This double-blind randomised controlled trial studied brain scans from people with major depressive disorder treated with psilocybin or escitalopram and found that the two treatments caused opposite changes in brain organisation. Baseline brain measures also helped distinguish who responded to each treatment.

Published
Journal
Biorxiv
Authors
Dagnino, P. C., Acero-Pousa, I., Zamora-López, G., Escrichs, A., Erritzoe, D., Nutt, D. J., Carhart-Harris, R. L., Sanz Perl, Y., Kringelbach, M. L., Deco, G.
Open Accessindividual

EEG microstate dynamics during psilocybin intoxication relate to acute experience and persisting psychological changes

This double-blind, randomised, placebo-controlled crossover study (n=15) in healthy volunteers found that psilocybin altered the timing of EEG brain-state patterns during peak intoxication, with faster switching between states but largely preserved overall state coverage. These changes were linked to the intensity of the acute experience and to self-reported psychological changes 28 days later.

Published
Journal
Biorxiv
Authors
Jajcay, N., Vejmola, Č., Korčák, J., Tylš, F., Viktorinová, M., Viktorin, V., Bravermanová, A., Androvičová, R., Balíková, M., Horacek, J., Brunovský, M., Hlinka, J., Palenicek, T.

Quick Facts

Papers Indexed
50
Publisher
openRxiv
Website
Visit